RECENT NEWS: SEED Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania. Read more

SEED Therapeutics’ Mission

 

To break through the scientific barriers to discovering Molecular Glues for effective therapy and cures for the world’s most debilitating diseases and disorders.

Collaborating with an unparalleled team of world-leading experts in the Ubiquitin Proteasome System and the field of Targeted Protein Degradation.  SEED Therapeutics is advancing its groundbreaking Molecular Glues discovery platform for the treatment of multiple indications, including cancer, neurodegradation, and infectious diseases.

DRUG DISCOVERY

About Seed Therapeutics

SEED Therapeutics: A focus on Molecular Glues

SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use Molecular Glues to attack protein targets previously believed to be ”undruggable.”

Natures Protein Recycling Mechanism
Molecular Glues
Scientific Challenges of Molecular Glue Discovery
SEED Leadership Team

PIPELINE

pipeline
Seed Therapeutics Pipeline Chart

THE TEAM

leadership
Click below to learn more about SEED Therapeutics’ leadership 
our leadership

LEADERSHIP TEAM

board of directors

BOARD OF DIRECTORS

NEWSROOM

communications

Press Releases

 

June 23, 2023
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
Continue reading >

July 01, 2022
SEED Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania
Continue reading >

November 13, 2020
BeyondSpring Subsidiary, SEED Therapeutics, Announces Research Collaboration and License Agreement with Lilly
Continue reading >

August 10, 2020
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Eli Lilly
Continue reading >

August 7, 2020
BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform
Continue reading >

October 14, 2020
SEED Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
Continue reading >

August 10, 2020
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Eli Lilly
Continue reading >

August 7, 2020
BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform
Continue reading >

PARTNERS

leadership team

Partners

Eli Lilly and Company

CAREERS

careers

Make a difference in improving human health